Literature DB >> 11780925

Sperm cryopreservation for men with nonmalignant, systemic diseases: a descriptive study.

Pavithra Ranganathan1, Ayman M Mahran, Jorge Hallak, Ashok Agarwal.   

Abstract

Cytotoxic drugs and immunosuppressive therapies are used to treat patients with nonmalignant, nontesticular systemic diseases. These therapies can permanently suppress spermatogenesis. Sperm cryopreservation before treatment theoretically could give these men the opportunity to achieve a pregnancy with a woman later in life when the couple decides to do so. However, it is not known whether pretreatment sperm quality in these men is good enough to be used for assisted reproductive techniques. The main objective of this study was to determine the usefulness of cryopreservation in this patient population by: 1) assessing their pretreatment semen quality (eg, count, motility, and motion kinetics) and comparing it with that of healthy donors before and after cryopreservation; 2) comparing patients' pretreatment semen characteristics with World Health Organization reference values for normal sperm; and 3) examining the differences in semen parameters among patient groups. Semen specimens were obtained from 25 healthy donors and from 23 patients with a variety of disorders (12 had autoimmune disorders, 4 had kidney disorders, 3 had diabetes, 2 had ulcerative colitis, and 2 had heart transplants). All patients, except those with diabetes, required immunosuppressive or cytotoxic therapy. Although the pretreatment quality of the semen of these patients was not as good as that of donors, semen samples were within the normal reference range of the World Health Organization. No statistically significant differences in sperm parameters were found within the 4 patient groups except for those with diabetes (n = 3), who showed poorer sperm counts (P < .04). However, no conclusive evidence can be reached due to the small sample size. Our results indicate that pretreatment semen quality in these patients is adequate for reproductive techniques. We believe that cryopreservation should be offered to patients of reproductive age with disease or treatment regimens that may cause infertility.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11780925     DOI: 10.1002/jand.2002.23.1.71

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  5 in total

Review 1.  Practical issues and challenges in the diagnosis and treatment of pulmonary sarcoidosis.

Authors:  Surinder K Jindal
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  MicroRNA-34a targets sirtuin 1 and leads to diabetes-induced testicular apoptotic cell death.

Authors:  Dan Jiao; Huan Zhang; Ziping Jiang; Wenlin Huang; Zhuo Liu; Zhaohui Wang; Yonggang Wang; Hao Wu
Journal:  J Mol Med (Berl)       Date:  2018-07-21       Impact factor: 4.599

3.  NRF2 Plays a Critical Role in Both Self and EGCG Protection against Diabetic Testicular Damage.

Authors:  Chenyu Pan; Shengzhu Zhou; Junduo Wu; Lingyun Liu; Yanyan Song; Tie Li; Lijuan Ha; Xiaona Liu; Fuchun Wang; Jingyan Tian; Hao Wu
Journal:  Oxid Med Cell Longev       Date:  2017-06-18       Impact factor: 6.543

Review 4.  Autophagy Induced by ROS Aggravates Testis Oxidative Damage in Diabetes via Breaking the Feedforward Loop Linking p62 and Nrf2.

Authors:  Yuanyuan Tian; Wei Song; Dongsheng Xu; Xiao Chen; Xiaojiao Li; Yuguang Zhao
Journal:  Oxid Med Cell Longev       Date:  2020-05-18       Impact factor: 6.543

5.  Long-term sperm cryopreservation does not affect post-thaw survival rates.

Authors:  Juliana R Pariz; Rosa Alice C Monteiro; Jorge Hallak
Journal:  JBRA Assist Reprod       Date:  2020-01-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.